Literature DB >> 22304847

Investigation of trypanothione reductase inhibitory activity by 1,3,4-thiadiazolium-2-aminide derivatives and molecular docking studies.

Raquel F Rodrigues1, Denise Castro-Pinto, Aurea Echevarria, Camilla M dos Reis, Catarina N Del Cistia, Carlos Mauricio R Sant'Anna, Filipa Teixeira, Helena Castro, Marilene Canto-Cavalheiro, Leonor L Leon, Ana Tomás.   

Abstract

The biological activities of a series of mesoionic 1,3,4-thiadiazolium-2-aminide derivatives have been studied. The most active compounds (MI-HH; MI-3-OCH(3); MI-4-OCH(3) and MI-4-NO(2)) were evaluated to determine their effect on trypanothione reductase (TryR) activity in Leishmania sp. and Trypanosoma cruzi. Among the assayed compounds, only MI-4-NO(2) showed enzyme inhibition effect on extracts from different cultures of parasites, which was confirmed using the recombinant enzyme from T. cruzi (TcTryR) and Leishmania infantum (LiTryR). The enzyme kinetics determined with LiTryR demonstrated a non-competitive inhibition profile of MI-4-NO(2). A molecular docking study showed that the mesoionic compounds could effectively dock into the substrate binding site together with the substrate molecule. The mesoionic compounds were also effective ligands of the NADPH and FAD binding sites and the NADPH binding site was predicted as the best of all three binding sites. Based on the theoretical results, an explanation at the molecular level is proposed for the MI-4-NO(2) enzyme inhibition effect. Given TryR as a molecular target, it is important to continue the study of mesoionic compounds as part of a drug discovery campaign against Leishmaniasis or Chagas' disease. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304847     DOI: 10.1016/j.bmc.2012.01.009

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  Mesoionic compounds with antifungal activity against Fusarium verticillioides.

Authors:  Rojane de Oliveira Paiva; Lucimar Ferreira Kneipp; Camilla Moretto dos Reis; Aurea Echevarria
Journal:  BMC Microbiol       Date:  2015-02-04       Impact factor: 3.605

3.  Bioassay-based Corchorus capsularis L. leaf-derived β-sitosterol exerts antileishmanial effects against Leishmania donovani by targeting trypanothione reductase.

Authors:  Pijush Kanti Pramanik; Sajal Chakraborti; Angshuman Bagchi; Tapati Chakraborti
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.379

4.  Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery.

Authors:  Crhisllane Rafaele Dos Santos Vasconcelos; Antonio Mauro Rezende
Journal:  Front Chem       Date:  2021-04-27       Impact factor: 5.221

5.  Developments in diagnosis and antileishmanial drugs.

Authors:  Prachi Bhargava; Rajni Singh
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-18

Review 6.  Recent Advances in the Discovery of Novel Antiprotozoal Agents.

Authors:  Seong-Min Lee; Min-Sun Kim; Faisal Hayat; Dongyun Shin
Journal:  Molecules       Date:  2019-10-28       Impact factor: 4.411

7.  Evaluation of Novel Chalcone-Thiosemicarbazones Derivatives as Potential Anti-Leishmania amazonensis Agents and Its HSA Binding Studies.

Authors:  Edinéia Pastro Mendes; Carla Marins Goulart; Otávio Augusto Chaves; Viviane Dos S Faiões; Marilene M Canto-Carvalho; Gerzia C Machado; Eduardo Caio Torres-Santos; Aurea Echevarria
Journal:  Biomolecules       Date:  2019-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.